Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1698199 | 0.96 | OPRL1 (0.36) | DRD2DRD3CXCR4OPRL1KCNH2 | |
| SCHEMBL1698196 | 0.92 | CXCR4 (0.43) | CXCR4KCNH2 | |
| SCHEMBL1698223 | 0.88 | OPRL1 (0.40) | DRD2DRD3CXCR4OPRL1KCNH2 | |
| SCHEMBL1698226 | 0.88 | CXCR4 (0.41) | CXCR4KCNH2 | |
| SCHEMBL1701122 | 0.84 | CXCR4 (0.38) | CXCR4KCNH2 | |
| SCHEMBL25515629 | 0.81 | OPRL1 (0.40) | DRD2CXCR4OPRL1KCNH2KDM4E | |
| SCHEMBL2669656 | 0.81 | OPRL1 (0.40) | DRD2CXCR4OPRL1KCNH2KDM4E | |
| SCHEMBL1698228 | 0.80 | OPRL1 (0.40) | DRD2DRD3CXCR4OPRL1KCNH2 | |
| SCHEMBL1698222 | 0.79 | CXCR4 (0.44) | CXCR4KCNH2 | |
| SCHEMBL1698203 | 0.79 | OPRL1 (0.34) | OPRL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933231-B2 | Organic compounds | GIVAUDAN SA | 2015-01-13 | — | — | US | claimed |
| US-20130129655-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2013-05-23 | — | — | US | claimed |
| WO-2011160254-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | claimed |
| US-11066399-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-13 | — | — | US | disclosed |
| CN-107072911-B | Malodor reducing compositions | 奇华顿股份有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20170290757-A1 | MALODOR REDUCING COMPOSITIONS | GIVAUDAN S.A. (CH) | 2017-10-12 | — | — | US | disclosed |
| US-8933231-B2 | Organic compounds | GIVAUDAN SA | 2015-01-13 | — | — | US | disclosed |
| US-8933231-B2 | Organic compounds | GIVAUDAN SA | 2015-01-13 | — | — | US | disclosed |
| US-8933231-B2 | Organic compounds | GIVAUDAN SA | 2015-01-13 | — | — | US | disclosed |
| US-20130129655-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2013-05-23 | — | — | US | disclosed |
| US-20130129655-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2013-05-23 | — | — | US | disclosed |
| US-20130129655-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2013-05-23 | — | — | US | disclosed |
| EP-2584916-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011161163-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161163-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011160254-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011160254-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139472-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | DRD2 2561/4885DRD3 3680/4885CXCR4 2203/4885 |
| US-20130129655-A1 | Organic Compounds | C9, C5, TRPA1 | DRD2 750/4885DRD3 576/4885CXCR4 1601/4885 |
| US-11066399-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | DRD2 2761/4885DRD3 3649/4885CXCR4 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.